Triangle Pharmaceuticals, Inc.

Jan 06, 03
18:03 ET	Triangle Announces Filing of Emtricitabine (Coviracil) With EMEA
Nov 06, 02
18:30 ET	Triangle Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter 2002
Nov 04, 02
08:06 ET	Coviracil(R) NDA for the Treatment of HIV Disease Accepted by the Food and Drug Administration
Oct 07, 02
08:00 ET	Triangle Pharmaceuticals, Inc. to Present at the UBS Warburg Global Life Sciences Conference
Sep 27, 02
09:30 ET	Once-Daily Coviracil(R) Regimen Superior to Zerit(R) in FTC-301 Clinical Trial
Sep 17, 02
18:00 ET	Triangle Pharmaceuticals Announces Final Settlement Of Patent Disputes Involving Amdoxovir (DAPD)
Sep 04, 02
18:00 ET	Triangle Pharmaceuticals, Inc. Submits New Drug Application for Coviracil(R) For the Treatment of HIV Disease
Aug 13, 02
06:00 ET	Triangle Pharmaceuticals, Inc. Reports Financial Results For Second Quarter 2002
Aug 05, 02
18:02 ET	Triangle Pharmaceuticals Names Daniel G. Welch as Chairman and CEO
Jul 30, 02
18:27 ET	Triangle Pharmaceuticals, Inc. Announces Data Safety Monitoring Board's Recommendation to Unblind Coviracil Pivotal Trial Early
18:24 ET	Triangle Pharmaceuticals, Inc. Announces Reacquisition of Product Rights From Abbott Laboratories
Jun 10, 02
09:02 ET	Triangle Pharmaceuticals, Inc. Announces Final Settlement of Patent Disputes Involving Its Late Stage Drug Candidate Coviracil(R)
Apr 30, 02
18:31 ET	Triangle Pharmaceuticals, Inc. Reports Financial Results For First Quarter 2002
Apr 24, 02
15:14 ET	Triangle Pharmaceuticals, Inc. Invites You to Join a Conference Call To Discuss Its First Quarter 2002 Financial Results
Feb 07, 02
18:31 ET	Triangle Pharmaceuticals, Inc. Reports Financial Results For Fourth Quarter and Year Ended December 31, 2001
Feb 05, 02
08:30 ET	Triangle Pharmaceuticals, Inc. Invites You to Join a Conference Call To Discuss Its Fourth Quarter 2001 Financial Results
Jan 29, 02
09:43 ET	Dr. David Barry, 58, Founder and CEO of Triangle Pharmaceuticals, Passes Away
Jan 17, 02
18:31 ET	Triangle Pharmaceuticals Plans 3rd Quarter 2002 NDA Submission for Coviracil(R) (emtricitabine) and Discontinues Development of Coactinon(R) (emivirine)